With targeted coverage of 16 biomarkers associated with AML, including FLT3 and NPM1, the SureSeq™ Myeloid MRD Plus NGS Panel is optimised for MRD characterisation. Users benefit from robust detection of complex and challenging mutations such as FLT3 internal tandem duplications (ITDs) exceeding 300 base pairs, to ensure they can obtain comprehensive genomic insights from their samples. Its focused design enables high-precision variant detection without the increased sequencing costs typically associated with broader panels. Additionally, by leveraging SureSeq’s refined bait design strategy, the panel achieves ultra-high sensitivity, detecting variants at allele frequencies as low as 0.01%, providing an earlier and more complete picture of the sample's MRD status.
Intelligently designed in collaboration with leading myeloid cancer experts, the SureSeq™ Myeloid Fusion Panel ensures results meet the latest clinical research recommendations by efficiently identifying over 30 key AML-associated fusions, including KMT2A and MECOM fusions, in a single assay. By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.
Both panels are fully compatible with the existing end-to-end Universal NGS Complete Workflow Solution, and complimentary* NGS data analysis software, Interpret, to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resources. Interpret includes longitudinal visualisation of MRD dynamics over time – including SNVs, indels and ITDs. Available as a secure cloud-based platform or local installation, Interpret offers user-friendly pre-configured analysis pipelines that streamline laboratory workflows and accelerate implementation. Additionally, customisation options allow users to tailor their analysis to meet their specific clinical research needs.
Carlos Martínez Pons, Head of Sysmex Life Science EMEA: “These new SureSeq™ NGS panels strengthen Sysmex Life Science’s commitment to providing the most advanced tools for the genetic characterisation of haemato-oncological samples. By combining our SureSeq™ NGS solutions with our CytoCell® FISH portfolio, laboratories can gain deeper insights into blood cancer biology—empowering clinical scientists with the clarity they need.”
For more information about the SureSeq™ Myeloid MRD, Myeloid Fusion NGS panels and other Sysmex genomics solutions, please visit: https://www.sysmex-europe.com/products/life-science/next-generation-sequencing-sureseq-ngs/
*Subject to fair usage policy.
About Sysmex Europe Life Science
Sysmex supports healthcare professionals and patients around the world with a broad range of medical diagnostics products and solutions in a variety of fields. Our multi-functional solutions work together with high-quality reagents and reliable service and support to create a better healthcare journey for all. In the field of life science, we have an ever-growing portfolio of solutions used throughout the pathway of cancer care in prevention, detection, diagnosis and monitoring. The mission is to support pathologists and oncologists by delivering essential genetic information, as quickly as possible.
Sysmex Europe SE, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information, visit www.sysmex-europe.com.
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision-makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers – not only by sharing its expertise of 30 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. With OGT’s precision medicine partnerships, we strive to accelerate clinical trial assay and companion diagnostic development programmes to help our partners make the right decisions every time. Dedicated to improving clinical care, OGT believes that through partnership – together – we’ll achieve more.
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.
